SCHEMBL5135599

SCHEMBL5135599

CCCCN(Cc1ccc(C)cc1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCC

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
CRHR1 P34998 2/20 0.42
TP53 P04637 1/20 0.39
TSHR P16473 3/20 0.39
ATP4A P20648 2/20 0.39
ATP4B P51164 2/20 0.39
HSD11B1 P28845 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 2/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
BCHE P06276 1/20 0.37
HDAC1 Q13547 1/20 0.37
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5070130 0.96 C5AR1 (0.47) C5AR1CRHR1TP53TSHRATP4A
SCHEMBL5134816 0.94 CRHR1 (0.44) C5AR1CRHR1TSHRATP4AATP4B
SCHEMBL5135456 0.94 C5AR1 (0.43) C5AR1CRHR1TSHRATP4AATP4B
SCHEMBL5136089 0.92 CRHR1 (0.43) C5AR1CRHR1TP53TSHRATP4A
SCHEMBL5136269 0.92 CRHR1 (0.42) C5AR1CRHR1TSHRATP4AATP4B
SCHEMBL5134969 0.92 C5AR1 (0.41) C5AR1CRHR1TSHRATP4AATP4B
SCHEMBL5136813 0.92 C5AR1 (0.41) C5AR1CRHR1TSHRATP4AATP4B
SCHEMBL5136173 0.91 C5AR1 (0.47) C5AR1CRHR1TP53TSHRHSD11B1
SCHEMBL5137489 0.90 C5AR1 (0.48) C5AR1CRHR1TSHRATP4AATP4B
SCHEMBL5134667 0.90 C5AR1 (0.43) C5AR1CRHR1TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed